Silver Bullet Therapeutics launched OrthoFuzIon, an antimicrobial bone screw indicated for open reduction and internal fixation (ORIF) fracture surgeries. OrthoFuzion screws are plated to inhibit microbial colonization and reduce implant-related infection in revision surgery due to implant infection or primary surgery in patients who are at-risk of implant infections.
Silver Bullet Therapeutics has developed a coating for bone screws since they penetrate the cortical shell of a bone into the intramedullary space to not only alleviate the morbidity and the costs associated orthopedic infection complications, but minimize the disincentive on caring for high-risk patients.
Paul Chirico, President and CEO of Silver Bullet Therapeutics, said, “Silver Bullet is very excited to be launching our product line at the prestigious German Society of Orthopedics with Argomedical, our respected distribution partner. Patients who receive revision surgery due to an implant related infection or those that are at risk of implant infections from a primary surgery will benefit from the technology and significantly broad product offering.”
Silver Bullet Therapeutics launched OrthoFuzIon, an antimicrobial bone screw indicated for open reduction and internal fixation (ORIF) fracture surgeries. OrthoFuzion screws are plated to inhibit microbial colonization and reduce implant-related infection in revision surgery due to implant infection or primary surgery in patients who are at-risk...
Silver Bullet Therapeutics launched OrthoFuzIon, an antimicrobial bone screw indicated for open reduction and internal fixation (ORIF) fracture surgeries. OrthoFuzion screws are plated to inhibit microbial colonization and reduce implant-related infection in revision surgery due to implant infection or primary surgery in patients who are at-risk of implant infections.
Silver Bullet Therapeutics has developed a coating for bone screws since they penetrate the cortical shell of a bone into the intramedullary space to not only alleviate the morbidity and the costs associated orthopedic infection complications, but minimize the disincentive on caring for high-risk patients.
Paul Chirico, President and CEO of Silver Bullet Therapeutics, said, “Silver Bullet is very excited to be launching our product line at the prestigious German Society of Orthopedics with Argomedical, our respected distribution partner. Patients who receive revision surgery due to an implant related infection or those that are at risk of implant infections from a primary surgery will benefit from the technology and significantly broad product offering.”
Copy to clipboard 
